Why the CNS boom owes its success to breakthroughs in neurological pathologies - Pharmaceutical Technology

Shifting emphasis from symptoms to biomarkers has bolstered sector confidence in emerging CNS therapies. Shifting emphasis from symptoms to biomarkers has bolstered sector confidence in emerging CNS therapies. Jo Shorthouse, Maha Radhakrishnan, Antti Vuolanto, Jim Allpress, and Kevin Dlagaard explained why they think biomolecular understanding is behind investor confidence. Credit: Frankie Fattorini/GlobalData. Experts say we can thank an improved understanding of the biology behind central nervous system (CNS) diseases for the resurgence of the sector, facilitating heightened confidence among investors to invest in earlier, more innovative therapies. A panel comprised of pharma, biotech, and investor representatives agreed a more robust…

Source: Pharmaceutical Technology